Who is the manufacturer of Platinib? how to buy

Pralsetinib (Pralsetinib) is produced by Blueprint Medicines Corporation, which is committed to developing precise treatment options for cancer patients to improve their quality of life. Platinib is an innovative drug developed by the company. It is an oral RET (rearrangement combined) inhibitor and has a high degree of selectivity and inhibitory effect on RET gene mutations. It has gained widespread attention and recognition around the world. Its launch provides new treatment hope for cancer patients with RET gene mutations.

Platinib is a drug that inhibits the growth and spread of certain cancer cells, but it does not completely eliminate the cancer. Treating cancer requires a combination of multiple treatments and an individualized treatment plan based on the patient's specific conditions. Patients need to actively cooperate with doctors’ treatment suggestions and maintain good living habits and mentality to improve treatment effects and quality of life.

In China, platinib has been approved by the National Medical Products Administration in March 2021 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). This important development means that Chinese patients can also get treatment opportunities with this innovative drug, bringing new hope and development opportunities to the field of cancer treatment in China. Platinib is a prescription drug and must be purchased and used with a doctor's prescription. If patients need to use this drug to treat tumors with RET gene mutations, they can choose regular channels (pharmacies or hospitals) when purchasing the drug to ensure the quality and safety of the drug.